A study linking popular weight loss drug to suicide risk again raises long-standing safety questions

Editor’s Note: If you or someone you know is struggling with suicidal thoughts or mental health matters, please call the 988 Suicide & Crisis Lifeline by dialing 988 to connect with a trained counselor, or visit the 988 Lifeline website.

People taking semaglutide, the popular medication for diabetes and weight loss, are more likely to report having thoughts of suicide compared with those taking other drugs, according to a new study of an international drug safety database. But the finding is the latest see-saw of scientific evidence on the risk of depression and suicide tied to the popular medications — and critics say evidence that the drugs cause problems with mood is limited.

A study linking popular weight loss drug to suicide risk again raises long-standing safety questions

Related:

Ian Douglas, London School of Hygiene & Tropical Medicine:

I am an epidemiologist, currently funded by GlaxoSmithKline. I initially studied physiology at BSc and PhD level in Manchester. Since then, I spent several years at the UK Medicines & Healthcare Products Regulatory Agency and in the pharmaceutical industry investigating adverse effects of drugs – both in clinical trials and post-marketing. I completed the MSc in epidemiology at LSHTM in 2005.

Previously:

Medicare to cover obesity drugs, but not for weight loss

Wegovy, Rybelsus, and Ozempic, are the different brand names for Semaglutide. They have a black box warning for Medullary thyroid cancer.* 🤦🏼‍♀️

Related:

Wegovy side effects: What you should know

*Obesity and Cancer

Everything We Learned From Oprah’s Weight Loss Special

Mounjaro:

Using Mounjaro may increase your risk of developing thyroid cancer.

Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs

Source

Lawmakers raising national security concerns and seeking to disconnect a major Chinese firm from U.S. pharmaceutical interests have rattled the biotech industry. The firm is deeply involved in development and manufacturing of crucial therapies for cancer, cystic fibrosis, H.I.V. and other illnesses.

Chinese Company Under Congressional Scrutiny Makes Key U.S. Drugs

Latest:

US bill to restrict WuXi AppTec, Chinese biotechs revised to give more time to cut ties

Scientific Misconduct and Fraud: The Final Nail in Psychiatry’s Antidepressant Coffin

“. . . if the major media picks up on this story, they will have the chance to report on what arguably is the worst—and most harmful—scandal in American medical history”

Robert Whitaker, publisher of madinamerica.com, January 3, 2024

Historically, there have always been some patients who report that any treatment for depression—including bloodletting—has worked for them, but science demands that for a treatment to be deemed truly effective, it must work better than a placebo or the passage of time without any treatment. This is especially important for antidepressant drugs—including Prozac, Zoloft, and other selective serotonin reuptake inhibitors (SSRIs), as well as Effexor, Cymbalta, and other serotonin and norepinephrine reuptake inhibitors (SNRIs)—because all of these drugs have uncontroversial troubling side effects.

Scientific Misconduct and Fraud: The Final Nail in Psychiatry’s Antidepressant Coffin

Related:

Once Radical Critiques of Psychiatry are Now Mainstream, So What Remains Taboo?

Psychedelic Drugs Are Rushing Towards Approval for Therapy. Here’s What’s Next